No Data
No Data
cms (00867.HK) Chairman Lin Gang increased his shareholding by 0.5 million shares.
According to the latest equity disclosure data of the Stock Exchange, on August 26, 2024, cms (00867.HK) director and chairman Lin Gang increased his shareholding by an average of 7.0546 Hong Kong dollars per share, acquiring 0.5 million shares for a total of approximately 3.5273 million Hong Kong dollars. After the acquisition, Lin Gang's latest shareholding amounted to 1,158,064,000 shares, increasing his shareholding percentage from 47.45% to 47.47%.
MedRhythms Announces New CMS Reimbursement Code for InTandem Rehabilitation System For Chronic Stroke Gait Impairment
Essen Health Care Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
China Medical System Holdings Limited (HKG:867) Just Released Its Half-Yearly Earnings: Here's What Analysts Think
Aesthetic medicine concept stocks are all on the rise. CMS (00867) rose 9.47%. Institutions point out that upstream manufacturers in the aesthetic medicine field have stronger market seizing abilities.
Jingu finance | Aesthetic medicine concept stocks are all on the rise, with Cms (00867) up 9.47%, Modern dental (03600) up 4.93%, Sihuan pharm (00460) up 3.85%, Ec healthcare (02138) up 2.86%, Fosun pharma (02196) up 2.6%, Reyoung pharm (06639) up 2.27%, and Haohai biotec (06826) up 1.95%. The open source securities research report pointed out that investment opportunities in the aesthetic medicine and cosmetic industries should be taken into account. Upstream manufacturers of aesthetic medicine have stronger market seizing ability in differentiation, and in the long run, they can achieve higher penetration rate and localization.
No Data